Edition:
India

Dermira Inc (DERM.OQ)

DERM.OQ on NASDAQ Stock Exchange Global Select Market

8.63USD
23 Aug 2019
Change (% chg)

$-0.35 (-3.90%)
Prev Close
$8.98
Open
$8.92
Day's High
$9.26
Day's Low
$8.62
Volume
170,288
Avg. Vol
241,008
52-wk High
$15.47
52-wk Low
$6.00

Latest Key Developments (Source: Significant Developments)

Dermira Says Q2 Revenue of $66.6 Million
Thursday, 8 Aug 2019 

Aug 7 (Reuters) - Dermira Inc ::DERMIRA REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 REVENUE $66.6 MILLION.Q2 REVENUE ESTIMATE $32 MILLION -- REFINITIV IBES DATA.AS OF JUNE 30, 2019, DERMIRA HAD CASH AND INVESTMENTS OF $327.2 MILLION.FOR QBREXZA, MANAGEMENT EXPECTS NET PRODUCT SALES FOR FULL YEAR 2019 IN LOW-$30 MILLION RANGE.FOR QBREXZA, MANAGEMENT EXPECTS GROSS-TO-NET DISCOUNT FOR SECOND HALF OF YEAR TO REMAIN AT APPROXIMATELY 40 PERCENT.SEES COLLABORATION AND LICENSE REVENUE RELATED TO ALMIRALL AGREEMENT OF APPROXIMATELY $2 MILLION FOR EACH OF THIRD AND FOURTH QUARTERS OF 2019.  Full Article

Almirall To Make Decision Regarding Exercise Of Its Lebrikizumab Option By Mid-Year
Monday, 3 Jun 2019 

June 3 (Reuters) - Almirall SA ::TO MAKE DECISION REGARDING EXERCISE OF OPTION TO EXCLUSIVELY LICENSE RIGHTS TO DEVELOP AND COMMERCIALIZE LEBRIKIZUMAB IN EUROPE BY MID-YEAR.IF ALMIRALL ELECTS TO EXERCISE ITS OPTION, COMPANY WILL PAY DERMIRA AN OPTION EXERCISE FEE OF $50 MILLION.  Full Article

Dermira Prices $130.0 Million Public Offering Of Common Stock
Wednesday, 20 Mar 2019 

March 19 (Reuters) - Dermira Inc ::DERMIRA PRICES $130.0 MILLION PUBLIC OFFERING OF COMMON STOCK.PRICING OF UNDERWRITTEN PUBLIC OFFERING OF 9.8 MILLION SHARES OF ITS COMMON STOCK AT A PRICE TO PUBLIC OF $13.25 PER SHARE.  Full Article

Dermira Reports Fourth Quarter And Full Year 2018 Financial Results And Provides Corporate Update
Wednesday, 27 Feb 2019 

Feb 26 (Reuters) - Dermira Inc ::DERMIRA REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q4 REVENUE $2.2 MILLION.Q4 REVENUE ESTIMATE $1.3 MILLION -- REFINITIV IBES DATA.QTRLY LOSS PER SHARE $1.70.  Full Article

Dermira Initiates Proof-Of-Concept Study To Evaluate Qbrexza (Glycopyrronium) Cloth
Friday, 22 Feb 2019 

Feb 22 (Reuters) - Dermira Inc ::DERMIRA INITIATES PROOF-OF-CONCEPT STUDY TO EVALUATE QBREXZA™ (GLYCOPYRRONIUM) CLOTH IN PATIENTS WITH PRIMARY PALMAR HYPERHIDROSIS.DERMIRA INC - STUDY WILL ASSESS IMPACT OF QBREXZA TREATMENT ON SWEAT SEVERITY IN PATIENTS WITH PRIMARY PALMAR HYPERHIDROSIS.DERMIRA INC - FINDINGS FROM STUDY ARE EXPECTED IN SECOND HALF OF 2019.  Full Article

Dermira Inc Says Secured Payer Coverage Of Qbrexza (Glycopyrronium)Cloth
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Dermira Inc ::DERMIRA INC - SECURED PAYER COVERAGE OF QBREXZA (GLYCOPYRRONIUM) CLOTH FOR THE TOPICAL TREATMENT OF PRIMARY AXILLARY HYPERHIDROSIS.  Full Article

Dermira enters into credit facility with Athyrium Capital Management
Tuesday, 4 Dec 2018 

Dec 4 (Reuters) - Dermira Inc ::DERMIRA ENTERS INTO CREDIT FACILITY WITH ATHYRIUM CAPITAL MANAGEMENT.DERMIRA INC - CLOSING OF A $125 MILLION CREDIT FACILITY WITH FUNDS MANAGED BY ATHYRIUM CAPITAL MANAGEMENT, LP.DERMIRA INC - AGREEMENT PROVIDES DERMIRA WITH UP TO $125 MILLION OF BORROWING CAPACITY AVAILABLE IN THREE TRANCHES, EACH BEARING INTEREST AT 10.75%/ANNUM.DERMIRA INC - INITIAL TRANCHE OF $35 MILLION WAS FUNDED AT CLOSING AND AN ADDITIONAL $90 MILLION WILL BE AVAILABLE AT DERMIRA'S OPTION.  Full Article

Dermira Reports Q2 Loss Per Share Of $0.57
Tuesday, 7 Aug 2018 

Aug 6 (Reuters) - Dermira Inc ::DERMIRA REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 REVENUE $39.1 MILLION VERSUS I/B/E/S VIEW $39.2 MILLION.QUARTERLY LOSS PER SHARE $0.57.  Full Article

Dermira Reports Q2 Loss Per Share Of $0.57
Tuesday, 7 Aug 2018 

Aug 6 (Reuters) - Dermira Inc ::DERMIRA REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 REVENUE $39.1 MILLION VERSUS I/B/E/S VIEW $39.2 MILLION.QUARTERLY LOSS PER SHARE $0.57.  Full Article

Dermira posts Q3 loss $4.30/shr, says FDA accepts NDA for glycopyrronium tosylate
Tuesday, 7 Nov 2017 

Nov 6 (Reuters) - Dermira Inc :Dermira reports third quarter 2017 financial results and announces that FDA accepts new drug application for glycopyrronium tosylate for the treatment of patients with primary axillary hyperhidrosis.Dermira Inc - ‍FDA decision on new drug application for glycopyrronium tosylate expected by June 30, 2018​.Dermira Inc - qtrly net loss per share, basic and diluted $4.30 ‍​.Dermira Inc - updating its financial guidance for full year 2017; now expects collaboration and license revenue of approximately $4.3 million for FY​.  Full Article